56 related articles for article (PubMed ID: 38658441)
1. The NM_033380.2 transcript of the
Liang L; Wu H; Zhao J
Front Genet; 2024; 15():1330525. PubMed ID: 38818038
[TBL] [Abstract][Full Text] [Related]
2. Exploring the link between Alport syndrome and multiple intracranial artery stenoses: a case report of COL4A5 mutation (118/120 characters).
Egashira S; Shiozawa M; Morita Y; Nozu K; Yoshihara F; Koga M
J Stroke Cerebrovasc Dis; 2024 Jun; ():107816. PubMed ID: 38880363
[TBL] [Abstract][Full Text] [Related]
3. Novel Mutations of
Gong WY; Liu FN; Yin LH; Zhang J
Biomed Res Int; 2021; 2021():6664973. PubMed ID: 33748275
[TBL] [Abstract][Full Text] [Related]
4. Trimerization profile of type IV collagen COL4A5 exon deletion in X-linked Alport syndrome.
Koyama Y; Suico MA; Owaki A; Sato R; Kuwazuru J; Kaseda S; Sannomiya Y; Horizono J; Omachi K; Horinouchi T; Yamamura T; Tsuhako H; Nozu K; Shuto T; Kai H
Clin Exp Nephrol; 2024 Apr; ():. PubMed ID: 38658441
[TBL] [Abstract][Full Text] [Related]
5. Trimerization and Genotype-Phenotype Correlation of
Kamura M; Yamamura T; Omachi K; Suico MA; Nozu K; Kaseda S; Kuwazuru J; Shuto T; Iijima K; Kai H
Kidney Int Rep; 2020 May; 5(5):718-726. PubMed ID: 32405592
[TBL] [Abstract][Full Text] [Related]
6. A Split-Luciferase-Based Trimer Formation Assay as a High-throughput Screening Platform for Therapeutics in Alport Syndrome.
Omachi K; Kamura M; Teramoto K; Kojima H; Yokota T; Kaseda S; Kuwazuru J; Fukuda R; Koyama K; Matsuyama S; Motomura K; Shuto T; Suico MA; Kai H
Cell Chem Biol; 2018 May; 25(5):634-643.e4. PubMed ID: 29526710
[TBL] [Abstract][Full Text] [Related]
7. Genetic and molecular dynamics analysis of two variants of the COL4A5 gene causing Alport syndrome.
Liang L; Wu H; Cai Z; Zhao J
BMC Med Genomics; 2023 Aug; 16(1):192. PubMed ID: 37596645
[TBL] [Abstract][Full Text] [Related]
8. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
9. CyclosporinA Derivative as Therapeutic Candidate for Alport Syndrome by Inducing Mutant Type IV Collagen Secretion.
Kuwazuru J; Suico MA; Omachi K; Kojima H; Kamura M; Kaseda S; Kawahara T; Hitora Y; Kato H; Tsukamoto S; Wada M; Asano T; Kotani S; Nakajima M; Misumi S; Sannomiya Y; Horizono J; Koyama Y; Owaki A; Shuto T; Kai H
Kidney360; 2023 Jul; 4(7):909-917. PubMed ID: 37143203
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy.
Matsuo M
JMA J; 2021 Jul; 4(3):232-240. PubMed ID: 34414317
[TBL] [Abstract][Full Text] [Related]
11. Genetic background, recent advances in molecular biology, and development of novel therapy in Alport syndrome.
Nozu K; Takaoka Y; Kai H; Takasato M; Yabuuchi K; Yamamura T; Horinouchi T; Sakakibara N; Ninchoji T; Nagano C; Iijima K
Kidney Res Clin Pract; 2020 Dec; 39(4):402-413. PubMed ID: 33214343
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome.
Yamamura T; Horinouchi T; Nagano C; Omori T; Sakakibara N; Aoto Y; Ishiko S; Nakanishi K; Shima Y; Nagase H; Takeda H; Rossanti R; Ye MJ; Nozu Y; Ishimori S; Ninchoji T; Kaito H; Morisada N; Iijima K; Nozu K
Kidney Int; 2020 Dec; 98(6):1605-1614. PubMed ID: 32712167
[TBL] [Abstract][Full Text] [Related]
13. Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5.
Yamamura T; Horinouchi T; Adachi T; Terakawa M; Takaoka Y; Omachi K; Takasato M; Takaishi K; Shoji T; Onishi Y; Kanazawa Y; Koizumi M; Tomono Y; Sugano A; Shono A; Minamikawa S; Nagano C; Sakakibara N; Ishiko S; Aoto Y; Kamura M; Harita Y; Miura K; Kanda S; Morisada N; Rossanti R; Ye MJ; Nozu Y; Matsuo M; Kai H; Iijima K; Nozu K
Nat Commun; 2020 Jun; 11(1):2777. PubMed ID: 32488001
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
